Curr Med Res Opin 2006 May; 22(5): 961-966 (Read article online)

Shi L, Juarez R, Hackworth J, Edgell ET, Haro JM, Vieta E, Tohen MF

OBJECTIVES: The objective of this study was to describe clinical and work functional outcomes associated with 6-month open-label olanzapine treatment for bipolar I disorder.METHODS: The study consisted of 249 patients entering a 6-month open label phase after 12 weeks of acute double-blind haloperidol or olanzapine treatment. Baseline for analysis was defined as the beginning of open-label treatment. The clinical outcomes were symptomatic remission defined by a Y-MRS total score